Craig Venter (Adam Jeffery/CNBC/NBCU Photo Bank via Getty Images)

Hu­man Longevi­ty makes a move to­ward Nas­daq with po­ten­tial SPAC deal, but noth­ing's fi­nal yet

An­ti-ag­ing com­pa­ny Hu­man Longevi­ty, found­ed by pi­o­neer­ing ge­nom­ic re­searcher Craig Ven­ter, is one step clos­er, po­ten­tial­ly, to be­com­ing a pub­lic com­pa­ny.

The start­up put out a press re­lease Mon­day af­ter­noon say­ing it has signed a “let­ter of in­tent” to re­verse merge with a SPAC run by for­mer Cred­it Su­isse CEO Tid­jane Thi­am, known as Free­dom Ac­qui­si­tion I Corp. If none of the SPAC in­vestors re­deem their shares and pull out at the float price of $10, Hu­man Longevi­ty will re­ceive $345 mil­lion.

Ven­ter’s for­mer com­pa­ny made sure to em­pha­size that Mon­day’s an­nounce­ment was far from a done deal, how­ev­er. Hu­man Longevi­ty made sev­er­al men­tions in its re­lease that there is no “as­sur­ance” the deal will go through. The en­ti­ties al­so did not file an SEC re­port, typ­i­cal­ly the stan­dard when an­nounc­ing a SPAC deal.

If the merg­er does take place, it will like­ly oc­cur in the third quar­ter this year and close in the first quar­ter of 2023, the com­pa­nies said. There was no in­for­ma­tion on a po­ten­tial PIPE fi­nanc­ing.

The Fi­nan­cial Times was the first to re­port that Ven­ter and Thi­am’s com­pa­nies were in SPAC merg­er dis­cus­sions.

Hu­man Longevi­ty got start­ed back in 2013 and of­fers ge­nom­ic se­quenc­ing and blood tests to clients, of­fer­ing per­son­al­ized meth­ods to fight ag­ing-re­lat­ed dis­eases. The com­pa­ny soon found it­self in a tu­mul­tuous pe­ri­od as Ven­ter was ac­cused of steal­ing trade se­crets as part of back-and-forth law­suits in 2018.

Though the com­pa­ny is seek­ing to raise $345 mil­lion through the re­verse-merg­er dance to Nas­daq, there’s no guar­an­tee it will do so giv­en the cur­rent mar­ket con­di­tions. Be­cause SPAC in­vestors don’t know the merg­er tar­get when they sign up, some re­tain the op­tion to take their mon­ey back out, with in­ter­est, at the SPAC’s IPO price — known as re­deem­ing shares.

With SPAC ac­tiv­i­ty falling from the pan­dem­ic-fu­eled boom of late 2020 and ear­ly 2021, Thi­am’s blank check com­pa­ny may see in­vestors re­deem their shares. Such a move would ring fa­mil­iar with the Sen­ti Bio SPAC con­sum­mat­ed ear­li­er this month, when the Tim Lu-run biotech net­ted on­ly $84.5 mil­lion of the $230 mil­lion avail­able in the SPAC trust, and $140.3 mil­lion over­all.

Ad­di­tion­al­ly, Free­dom Ac­qui­si­tion I Corp. has strug­gled to re­tain spon­sors, re­veal­ing in an SEC fil­ing this month that Pim­co, the world’s largest bond man­ag­er, gave up its SPAC stake. Pim­co was re­placed by an ad­vi­so­ry firm, Next G, af­fil­i­at­ed with Chi­nese en­tre­pre­neur Ed­ward Zeng.

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 

APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Reading about John Carroll’s pick of biotech’s most promising startups has become a treasured tradition. If you ever get curious about previous classes of the Endpoints 11, you can find all of them (plus a number of our other regular specials) here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.

In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Just one day after blockbuster Lynparza got access to another indication in China, its Big Pharma owners have decided to withdraw it in certain patients after reviewing Phase III data.

The two companies that work together on Lynparza decided to recall one of the indications several weeks ago in a specific type of ovarian cancer, Lynparza’s first indication when it was first FDA-approved in 2014. Initial data showed that rates of overall survival in patients with at least three rounds of chemo before getting on the PARP inhibitor were lower than in patients with less previous chemo treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

Fu­ji­film con­tin­ues CD­MO ex­pan­sion, break­ing ground on $435M UK site

Fujifilm’s CDMO arm, Fujifilm Diosynth, has been on a roll this month as the company has recently broken ground on a major project in Europe and it appears to be keeping up the momentum.

Fujifilm Diosynth announced that it has kicked off an expansion project for its microbial manufacturing facility at its campus in the town of Billingham, UK, in the northeast of England.

The 20,000 square-foot, £400 million ($435 million) expansion will add clean rooms, purification suites and a packing area along with more space for the manufacturing itself.

Solicitor General Elizabeth Prelogar

Should SCO­TUS hear Am­gen's Repatha case? So­lic­i­tor gen­er­al says no

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.

Phil Sharp, Nobel Prize laureate (L), and John Carroll, Endpoints News co-CEO (via Michael Last)

The End­points 11: Fire­side chat with No­bel Prize lau­re­ate Phil Sharp

The following Q&A has been edited for length and clarity.

John Carroll:

We’ve had a chance to talk a little bit before here about some of the things that you’ve done. Just really remarkably, a lot of the things that you’ve done early in your career puts you in the path with some amazing science that has had an absolutely huge impact in terms of what we’re seeing now on drug development and some of the new technologies that are coming out here, and not only the new technologies, but also some of the most remarkable people ever.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Klick Health gath­ers biotech and phar­ma lu­mi­nar­ies to dis­cuss in­dus­try in­no­va­tions, in­vest­ments and fu­ture

At Klick Health’s first Ideas Exchange conference with biotech and pharma industry insiders since before the pandemic began, it was no surprise many conversations included Covid topics. Yet while vaccines and treatments were discussed, so too were the effects on drug development, federal responses, health inequities — and what to do now and next.

George Yancopoulos, chief scientist and cofounder of Regeneron, opened the conference responding to a question from Acorda CEO Ron Cohen about the spotlight on the industry during Covid and some of the “flak” biopharma has taken in the past.